Maine Medicine Weekly Update - 02/12/2021  (Plain Text Version)

Return to Graphical Version

 

In this issue:
•  MMA Weekly State Vaccination Plan Update
•  MMA Leadership & Staff Share Condolences on Passing of George Smith
•  Maine PMP to Stay with Appriss System
•  Next Maine CDC COVID-19 Update for Clinicians with Stephen Sears, MD scheduled for Feb 25
•  Federal Government Finalizes Purchase of 200M COVID-19 Vaccines Doses
•  US CDC: Fully Vaccinated Meeting Criteria No Longer Required to Quarantine After Exposure
•  AMA President: Physicians & Medical Societies Can Play Vital Role Advocating for Strong Public Health
•  NEJM: The FDA’s Experience with Covid-19 Antibody Tests
•  NEJM: Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
•  Monoclonal Antibody Authorization from the FDA (Updated 02/09/21) & MaineCare Reimbursement
•  Guidance for Industry: Investigational COVID-19 Convalescent Plasma (Updated 02/11/20)
•  Maine Legislative Leadership COVID-19 Bill Set for Public Hearing Tuesday
•  Next MMA Legislative Call Will Be Wednesday, February 17th
•  Daniel Hanley Center for Health Leadership’s Renowned Physician Executive Leadership Institute – The Advanced Course Enrollment is OPEN
•  PPE Available Through the MMA & ActionPPE
•  A Message from Maine Responds: Volunteer Opportunity
MAINE LEGISLATURE
•  Maine Legislature Week 5 Update
•  Upcoming Public Hearings & Work Sessions; New Bills Introduced
UPCOMING EVENTS
•  Upcoming Specialty Society Meetings
•  Maine CDC Physicians To Host Regular Clinician COVID Vaccine Info Sessions
•  Suicide Prevention and Management in Healthcare Practice Settings: A Comprehensive Evidence-Based Approach
•  MOA VIRTUAL Midwinter Symposium - February 12th-14th
•  Maine CDC Annual Prevention Professionals Conference - March 2nd-3rd
•  AAP EQIPP Course: Immunizations - Strategies for Success (for RURAL Health Providers)
HEALTHCARE EMPLOYMENT OPPORTUNITIES
•  Physician (BC/BE in Family Medicine)
•  Nursing Director
•  Medical Director - Bucksport Regional Health Center
•  Rangeley Family Medicine seeks Physician

 

Maine PMP to Stay with Appriss System

Director of Opioid Response for the State of Maine, Gordon Smith directly messaged various stakeholder organizations this week to inform PMP users statewide that after months of deliberations and concerns expressed by clinicians, Maine has decided to retain the use of the Appriss Prescription Monitoring Program system rather than install and transition to a new system.

 

Director of Opioid Response for the State of Maine, Gordon Smith directly messaged various stakeholder organizations this week to inform PMP users statewide that after months of deliberations and concerns expressed by clinicians, Maine has decided to retain the use of the Appriss Prescription Monitoring Program system rather than install and transition to a new system. 

Please see the message below being sent to all current PMP users (data submitters and clinicians) from Rebecca Taylor, OBH Deputy Director for Research and Evaluation. 

Please address any questions you may have to Ms. Taylor using contact information listed below. 

Dear PMP User, 

Thank you for your patience and assistance during the PMP system transition. We are writing to provide you with an important update regarding this transition.

As you know, in August 2019 Maine DHHS made the determination to transition from the Appriss PMP system to a new PMP product offered by NIC/InforME: RxGov. This decision was based upon multiple factors, including the opportunity to access enhanced federal funding and the desire to enhance PMP reporting functionality. The new NIC/RxGov PMP was subsequently offered to Maine prescribers in the fall of 2020, while the Appriss AWARxE PMP remained functional and available to prescribers. After fully exploring this opportunity over the past several months and soliciting input from Maine clinicians, Maine DHHS has made the decision to retain the Appriss AWARxE PMP due to its superior performance, particularly related to issues of data validity, functionality, and reporting. Examples of the desired functionality that remain available from the Appriss AWARxE PMP include the following: 

  • Printing of patient histories, both individual patients and groups of patients
  • Ability to automatically view the use of controlled drugs from prescribers in Maine and New Hampshire, our contiguous state
  • Robust patient matching to allow clinicians see all records associated with a single patient
  • Availability of NarxCare, a visual clinical decision support tool that allows prescribers to see overlapping prescriptions of controlled substances and assess patient risk

In making this decision, DHHS is acutely aware of the need to minimize the administrative burden to Maine prescribers. Because the Appriss PMP system has remained fully operational throughout the transition period, prescribers currently enrolled in the Appriss PMP system will not be required to make any changes in their enrollment or registration. Prescribers who are using the NIC/RxGov PMP system are encouraged to return to using the Appriss AWARxE PMP as soon as possible.

All Maine healthcare providers, whether enrolled in the Appriss system or not, will receive emails with detailed Appriss PMP login instructions beginning in the next few days. Please note that these emails will come from Appriss Health.

As part of the reversion to the Appriss AWARxE PMP system, Maine DHHS looks forward to upcoming opportunities to engage PMP users in stakeholder engagement sessions to gather feedback on potential additional needs for enhanced PMP functionality, share existing solutions offered by the Appriss, and offer information about planned enhancements for the Appriss system. More information on those opportunities will be forthcoming soon. Questions about this transition or other aspects of the Maine PMP program can be directed to the Office of Behavioral Health PMP Team at: email: PMP@maine.gov or Phone: (207) 287-2595 Option 2.

Thank you,

Rebecca A. Taylor, Deputy Director

Office of Behavioral Health